Generic Ozempic Availability
Last updated on Apr 10, 2025.
Ozempic is a brand name of semaglutide, approved by the FDA in the following formulation(s):
OZEMPIC (semaglutide - solution;subcutaneous)
-
Manufacturer: NOVO
Approval date: December 5, 2017
Strength(s): 2MG/1.5ML (1.34MG/ML) [RLD] -
Manufacturer: NOVO
Approval date: April 9, 2019
Strength(s): 4MG/3ML (1.34MG/ML) [RLD] -
Manufacturer: NOVO
Approval date: March 28, 2022
Strength(s): 8MG/3ML (2.68MG/ML) [RLD] -
Manufacturer: NOVO
Approval date: October 6, 2022
Strength(s): 2MG/3ML (0.68MG/ML) [RLD]
Is there a generic version of Ozempic available?
No. There is currently no therapeutically equivalent version of Ozempic available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ozempic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Syringe device with a dose limiting mechanism and an additional safety mechanism
Patent 10,220,155
Issued: March 5, 2019
Inventor(s): Eiland Jacob & Enggaard Christian Peter & Moller Claus Schmidt & Markussen Tom Hede
Assignee(s): Novo Nordisk A/SA syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose.
Patent expiration dates:
- July 17, 2026✓✓
- July 17, 2026
-
Use of long-acting GLP-1 peptides
Patent 10,335,462
Issued: July 2, 2019
Inventor(s): Jensen Christine Bjoern
Assignee(s): Novo Nordisk A/SThe invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.
Patent expiration dates:
- June 21, 2033✓
- June 21, 2033✓✓
- June 21, 2033
-
Injection device with an end of dose feedback mechanism
Patent 10,357,616
Issued: July 23, 2019
Inventor(s): Moller Claus Schmidt & Radmer Bo & Nielsen Lars Ulrik & Enggaard Christian Peter
Assignee(s): Novo Nordisk A/SAn injection device with a dose delivering mechanism being adapted to provide a non-visual, e.g. audible and/or tactile, feedback signal when a set dose has been at least substantially injected. A first and a second part of the injection device are adapted to perform a relative rotational movement with respect to each other. The relative rotational movement causes at least two parts of the injection device to abut or engage, and this abutment or engagement causes the non-visual feedback signal to be generated. A very distinct and precise feedback is provided as compared to prior art axial solutions because the generation of the feedback signal is initiated by the relative rotational movement.
Patent expiration dates:
- January 20, 2026✓✓
- January 20, 2026
-
Automatic injection device with a top release mechanism
Patent 10,376,652
Issued: August 13, 2019
Inventor(s): Markussen Tom Hede
Assignee(s): Novo Nordisk A/SThe present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.
Patent expiration dates:
- January 20, 2026✓✓
- January 20, 2026
-
Syringe device with a dose limiting mechanism and an additional safety mechanism
Patent 11,097,063
Issued: August 24, 2021
Inventor(s): Eiland Jacob & Enggaard Christian Peter & Moeller Claus Schmidt & Markussen Tom Hede
Assignee(s): Novo Nordisk A/SA syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose.
Patent expiration dates:
- July 17, 2026✓✓
- July 17, 2026
-
Automatic injection device with a top release mechanism
Patent 11,311,679
Issued: April 26, 2022
Inventor(s): Markussen; Tom Hede
Assignee(s): Novo Nordisk A/S (Bagsvaerd, DK)The present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.
Patent expiration dates:
- January 20, 2026✓✓
- January 20, 2026
-
Injection device with torsion spring and rotatable display
Patent 11,446,443
Issued: September 20, 2022
Inventor(s): Moeller Claus Schmidt & Markussen Tom Hede & Enggaard Christian Peter
Assignee(s): Novo Nordisk A/SThe present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof.
Patent expiration dates:
- October 20, 2025✓✓
- October 20, 2025
-
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Patent 8,114,833
Issued: February 14, 2012
Inventor(s): Pedersen Tina Bjeldskov & Bonde Claude & Engelund Dorthe Kot
Assignee(s): Novo Nordisk A/SThe present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.
Patent expiration dates:
- August 13, 2025✓
- August 13, 2025
-
Acylated GLP-1 compounds
Patent 8,129,343
Issued: March 6, 2012
Inventor(s): Lau Jesper & Bloch Paw & Hansen Thomas Kruse
Assignee(s): Novo Nordisk A/SProtracted GLP-1 compounds and therapeutic uses thereof.
Patent expiration dates:
- December 5, 2031✓✓✓
- December 5, 2031✓✓✓
- December 5, 2031✓✓✓
- December 5, 2031
-
Acylated GLP-1 compounds
Patent 8,536,122
Issued: September 17, 2013
Inventor(s): Lau Jesper & Doerwald Florencio Zaragoza & Bloch Paw & Hansen Thomas Kruse
Assignee(s): Novo Nordisk A/SProtracted GLP-1 compounds and therapeutic uses thereof.
Patent expiration dates:
- March 20, 2026✓✓✓
- March 20, 2026✓✓✓
- March 20, 2026✓✓✓
- March 20, 2026
-
Injection device with torsion spring and rotatable display
Patent 8,684,969
Issued: April 1, 2014
Inventor(s): Moller Claus Schmidt & Markussen Tom Hede & Enggaard Christian Peter
Assignee(s): Novo Nordisk A/SThe present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof.
Patent expiration dates:
- October 20, 2025✓✓
- October 20, 2025
-
Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Patent 8,920,383
Issued: December 30, 2014
Inventor(s): Enggaard Christian Peter & Moller Claus Schmidt & Markussen Tom Hede
Assignee(s): Novo Nordisk A/SA mechanism for preventing setting of a dose, which exceeds the amount of a medicament in a reservoir in an injection device. The device comprises a threaded piston rod, a limiter and a driver. The three elements are arranged such that during dose setting, the limiter is moved towards an end-of-contend position, wherein dose setting is limited. The invention comprises an accumulative and a non-accumulative embodiment. The invention further relates to a mechanism for prevention ejection of a dose exceeding the set dose.
Patent expiration dates:
- July 17, 2026✓✓
- July 17, 2026
-
Automatic injection device with a top release mechanism
Patent 9,108,002
Issued: August 18, 2015
Inventor(s): Markussen Tom Hede
Assignee(s): Novo Nordisk A/SThe present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.
Patent expiration dates:
- January 20, 2026✓✓
- January 20, 2026
-
Dial-down mechanism for wind-up pen
Patent 9,132,239
Issued: September 15, 2015
Inventor(s): Møller Claus Schmidt & Markussen Tom Hede & Radmer Bo & Enggaard Christian Peter
Assignee(s): Novo Nordisk A/SThe present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising a ratchet arm () engaging a ring element () and a reset element () which acts on a knob located on the periphery of the ratchet arm () to move the ratchet arm () out of engagement with the ring element () in order to allow the set dose to be reduced.
Patent expiration dates:
- February 1, 2032✓✓
- February 1, 2032
-
Injection device with an end of dose feedback mechanism
Patent 9,457,154
Issued: October 4, 2016
Inventor(s): Moller Claus Schmidt & Radmer Bo & Nielsen Lars Ulrik & Engaard Christian Peter
Assignee(s): Novo Nordisk A/SAn injection device with a dose delivering mechanism being adapted to provide a non-visual, e.g. audible and/or tactile, feedback signal when a set dose has been at least substantially injected. A first and a second part of the injection device are adapted to perform a relative rotational movement with respect to each other. The relative rotational movement causes at least two parts of the injection device to abut or engage, and this abutment or engagement causes the non-visual feedback signal to be generated. A very distinct and precise feedback is provided as compared to prior art axial solutions because the generation of the feedback signal is initiated by the relative rotational movement. Feedback signal may be generated by a change in a rotational velocity of at least one part, e.g. by changing the pitch of a threaded portion or by engaging a non-rotating part and a rotating part, thereby causing the non-rotating part to start rotating. May alternatively be generated by building up and releasing a tension. The injection device is suitable for injecting insulin.
Patent expiration dates:
- September 27, 2027✓✓
- September 29, 2027✓✓
- September 27, 2027
-
Automatic injection device with a top release mechanism
Patent 9,616,180
Issued: April 11, 2017
Inventor(s): Markussen Tom Hede
Assignee(s): Novo Nordisk A/SThe present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.
Patent expiration dates:
- January 20, 2026✓✓
- January 20, 2026
-
Injection device with torsion spring and rotatable display
Patent 9,687,611
Issued: June 27, 2017
Inventor(s): Moeller Claus Schmidt & Markussen Tom Hede & Enggaard Christian Peter
Assignee(s): Novo Nordisk A/SThe present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof.
Patent expiration dates:
- February 27, 2027✓✓
- February 27, 2027
-
Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Patent 9,775,953
Issued: October 3, 2017
Inventor(s): Enggaard Christian Peter & Moller Claus Schmidt & Markussen Tom Hede
Assignee(s): Novo Nordisk A/SA mechanism for preventing setting of a dose, which exceeds the amount of a medicament in a reservoir in an injection device. The device can contain a threaded piston rod, a limiter and a driver. The three elements can be arranged such that during dose setting, the limiter is moved towards an end-of-content position, wherein dose setting is limited. The invention contains an accumulative and a non-accumulative embodiment. The invention further relates to a mechanism for preventing ejection of a dose exceeding the set dose.
Patent expiration dates:
- July 17, 2026✓✓
- July 17, 2026
-
Injection device with an end of dose feedback mechanism
Patent 9,861,757
Issued: January 9, 2018
Inventor(s): Moller Claus Schmidt & Radmer Bo & Nielsen Lars Ulrik & Enggaard Christian Peter
Assignee(s): Novo Nordisk A/SAn injection device with a dose delivering mechanism being adapted to provide a non-visual, e.g. audible and/or tactile, feedback signal when a set dose has been at least substantially injected. A first and a second part of the injection device are adapted to perform a relative rotational movement with respect to each other. The relative rotational movement causes at least two parts of the injection device to abut or engage, and this abutment or engagement causes the non-visual feedback signal to be generated. A very distinct and precise feedback is provided as compared to prior art axial solutions because the generation of the feedback signal is initiated by the relative rotational movement.
Patent expiration dates:
- January 20, 2026✓✓
- January 20, 2026
-
Dial-down mechanism for wind-up pen
Patent RE46363
Issued: April 11, 2017
Inventor(s): Moeller Claus Schmidt & Enggaard Christian Peter & Radmer Bo & Markussen Tom Hede
Assignee(s): Novo Nordisk A/SThe present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising dial-up cam arranged to receive and engage with a dial-up key, wherein the dial-up cam and the dial-up key are adapted to, upon rotation of a dose setting member in a first direction, cooperate to strain the torsion spring of the injection device, and a dial-down cam arranged to receive and engage with a dial-down key, wherein the dial-down cam and the dial-down key are adapted to, upon rotation of the dose setting member in a second direction, cooperate to release the torsion spring of the injection device, the second rotation direction being opposite to the first rotation direction.
Patent expiration dates:
- August 3, 2026✓✓
- August 3, 2026
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 28, 2025 - ADDITION OF A 3RD MAINTENANCE DOSE OF SEMAGLUTIDE
- January 28, 2028 - TO REDUCE THE RISK OF SUSTAINED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE
More about Ozempic (semaglutide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,507)
- Drug images
- Latest FDA alerts (5)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: GLP-1 Agonists (Incretin Mimetics)
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.